In Brief
This article was originally published in The Tan Sheet
Executive Summary
EFSA wraps up health claim evaluations
You may also be interested in...
Perrigo Relies On New Products For Fiscal Second-Half Boost
Planned launches of generic Claritin-D, Mucinex and Prevacid 24HR are expected to help Perrigo reach 12% to 14% consumer health care growth in fiscal 2012. Opportunities to gain from J&J and Novartis OTC recalls likely are minimal going forward, the private labeler says on its Q2 earnings call.
Perrigo Relies On New Products For Fiscal Second-Half Boost
Planned launches of generic Claritin-D, Mucinex and Prevacid 24HR are expected to help Perrigo reach 12% to 14% consumer health care growth in fiscal 2012. Opportunities to gain from J&J and Novartis OTC recalls likely are minimal going forward, the private labeler says on its Q2 earnings call.
Perrigo OTCs, Nutritionals Underperform Despite Record Overall Revenue
Perrigo delivered record first-quarter revenue but fell short of analyst expectations due to slowing growth in its consumer health care and nutritional units.